Rapport Therapeutics Inc (RAPP) FinancialsRAPPFinancialRapport Therapeutics Inc

Evaluating the bottom line, Rapport Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -425.11%, while the net margin is -382.36%. These profitability ratios, combined with a Return on Equity (ROE) of -39.96%, provide a clear picture of how effectively RAPP converts its operational activities into shareholder value.

In the context of the broader market, RAPP competes directly with industry leaders such as NUVB and KOD. With a market capitalization of $2.28B, it holds a significant position in the sector. When comparing efficiency, RAPP's gross margin of 100.00% stands against NUVB's 70.11% and KOD's N/A. Such benchmarking helps identify whether Rapport Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Rapport Therapeutics has shown a gross margin of 100% in Q1 2026, indicating potential for future profitability. However, the company reported a net loss of $56.6 million in Q2 2026, which is a concern for long-term investors.